Share on StockTwits

Medifast (NYSE:MED) EVP Jeannette M. Mills sold 3,000 shares of Medifast stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $28.03, for a total transaction of $84,090.00. Following the sale, the executive vice president now directly owns 20,116 shares of the company’s stock, valued at approximately $563,851. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Medifast (NYSE:MED) traded down 0.18% on Wednesday, hitting $27.97. 20,232 shares of the company’s stock traded hands. Medifast has a 52-week low of $23.02 and a 52-week high of $34.40. The stock has a 50-day moving average of $29.11 and a 200-day moving average of $29.46. The company has a market cap of $356.3 million and a P/E ratio of 16.61.

Medifast (NYSE:MED) last released its earnings data on Thursday, August 7th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.05. The company had revenue of $80.88 million for the quarter, compared to the consensus estimate of $87.30 million. During the same quarter in the previous year, the company posted $0.51 earnings per share. The company’s revenue for the quarter was down 16.7% on a year-over-year basis. On average, analysts predict that Medifast will post $1.75 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on MED shares. Analysts at Zacks downgraded shares of Medifast from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $25.50 price target on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of Medifast from $32.00 to $29.00 in a research note on Friday, August 8th. Finally, analysts at Wedbush cut their price target on shares of Medifast from $37.00 to $32.00 in a research note on Friday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the stock. Medifast presently has a consensus rating of “Hold” and an average target price of $29.10.

Medifast, Inc (NYSE:MED) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.